Point72 Europe (London) LLP Annexon, Inc. Transaction History
Point72 Europe (London) LLP
- $1.62 Billion
- Q4 2024
A detailed history of Point72 Europe (London) LLP transactions in Annexon, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 155,573 shares of ANNX stock, worth $437,160. This represents 0.05% of its overall portfolio holdings.
Number of Shares
155,573
Previous 159,953
2.74%
Holding current value
$437,160
Previous $946,000
15.64%
% of portfolio
0.05%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding ANNX
# of Institutions
156Shares Held
98.2MCall Options Held
146KPut Options Held
174K-
Satter Management Co., L.P.7.41MShares$20.8 Million71.99% of portfolio
-
Bvf Inc San Francisco, CA7MShares$19.7 Million1.34% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$18.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.3MShares$17.7 Million2.53% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.63MShares$15.8 Million0.07% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $134M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...